Other substances

mRBD

A candidate SARS-CoV-2 vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

mRBD is a candidate vaccine with mammalian cell expression-optimized SARS-CoV-2 spike protein RBD serving as the immunogen. The vaccine contains MF59 equivalent (AddaVax™) adjuvant. The mRBD formulation is thermally stable (Malladi et al., 2020).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment
Spike protein Protein factor Animal model Mixed substance 		guinea pigs 4.24

The candidate vaccine elicits high titres of neutralizing antibodies in guinea pigs. The mRBD polypeptide binds ACE2 fused with human Fc domain with KD of ca. 14.2 nM.

 Nov/23/2020

AI-suggested references

Link Publication date
Comparative Immunogenicity of the Recombinant Receptor-Binding Domain of Protein S SARS-CoV-2 Obtained in Prokaryotic and Mammalian Expression Systems
Jan/09/2022
Export (.csv)